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Cockroach allergy:
risk factor for asthma severity
Dear Editor,
Until the mid-1970s aeroallergens were regarded as
triggers of asthma attacks in individuals whose lungs were
genetically irritable. More recently, however, the role of
allergen exposure in the development of asthma has been
more clearly defined, and it is believed to have three basic
functions: a) exposure to some specific allergen(s), especially
in early life, makes genetically susceptible individuals develop
hypersensitivity; b) In these individuals, continuous exposure
to the allergen(s) increases the risk for bronchial
hyperresponsiveness (BHR) and; c) most individuals with
BHR have repeated episodes of airflow obstruction, which
may be triggered by several factors other than allergens, such
as cold air, tobacco smoke, stress, among others.
Thus, the relationship between exposure to allergens and
development of asthma seems to be restricted only to
individuals who developed type I hypersensitivity, i.e., atopic
individuals. Therefore, it is quite likely that: a) more than a
direct effect on lungs, the action of allergenic proteins may
result from immediate and late allergic reactions and b) even
though they act as triggers of asthma attacks, allergens per
se are the main cause of inflammation that coexists with
asthma in individuals who are genetically susceptible to
atopic disease.1
For some decades, it has been known that household dust
and mites may cause atopic sensitization, with the development
of different clinical symptoms. Among those aeroallergens
that play a role in the pathogenesis of respiratory allergies,
one should pay special attention to those produced by fungi,
cockroaches, pollen, and pet dander.
Cockroach infestation is a universal phenomenon, but,
although there are nearly 3,500 cockroach species all over the
world, few of them inhabit households. Sensitization to
cockroach allergens, a problem that predominantly affects
urban residents, has been more deeply implicated in the
etiology of asthma, mainly regarding more severe clinical
symptoms among socioeconomically underprivileged patients.2
In a study carried out in Sªo Paulo, which used skin tests
to determine atopic sensitization, we observed the remarkable
presence of sensitization to cockroach allergens (Blattella
germanica and Periplaneta americana) in a group of asthmatic
adolescents (22.3 and 16.5%, respectively) compared to
non-asthmatic individuals (controls) (0 and 0%, respectively).
In the asthmatic group, the rate of BHR was significantly
higher among sensitized adolescents, compared to non-
sensitized ones. These data were corroborated by the presence
of more severe asthma (higher frequency of wheezing episodes
and speech disorders due to wheezing in the past year)
among sensitized asthmatics.3
The diagnosis of respiratory allergies is based on the
correlation between clinical history and physical examination
specific to allergies, in addition to diagnostic test results. IgE
is the major antibody class involved in type I hypersensitivity.
Thus, the in vivo and in vitro tests for the diagnosis of allergy
are used to detect free IgE or cell membrane-bound IgE.
The study by Lopes et al.4 is of utmost importance, since
it shows the key role of cockroach allergens in atopic
sensitization in our setting and presents important facts
about the tests used for its diagnosis. A previous study found
32.8% of positive results for cockroach-specific IgE5 among
Brazilian atopic children treated at divisions of Pediatric
Allergy.
We congratulate the authors on the choice of the topic, on
their careful observations, and on the extremely appropriate
way by which they addressed the limitations and controversies
regarding the methods used for allergen-specific IgE
determination: in vivo (skin tests) and in vitro (specific IgE
measurement).
The authors adequately discuss a web of factors that may
influence the results of these tests and that should always be
taken into account. Among these factors are the quality and
power of extracts, the techniques used, the possibility of
cross-reactions and the accuracy of interpretation.
No less important was the discussion about total IgE
determination, which, as the authors stated, is often requested,
but has a too limited and arguable application in the diagnosis
of allergies.
It should be underscored that it is impossible to diagnose
allergy based solely on the results of laboratory (in vivo or
in vitro) tests for specific IgE. The diagnosis must be hinged
on the correlation between clinical history, physical
examination, and test results.
Despite the improvements in, and the growing importance
of, in vitro tests as auxiliary tools in the diagnosis of type I
allergies in the last few decades, in vivo skin testing is the
most adequate method, from a clinical standpoint, for the
assessment of atopic sensitization.
For this purpose, the qualitative determination of the
allergens to be used in the batteries of tests should always
take the regional characteristics of aeroallergen prevalence
into consideration, i.e., potential and known allergen exposure
for the region and area of the country where the patient lives.6
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characterized by a more severe course of the disease. In a
study undertaken in the city of Curitiba, Brazil, which included
303 atopic asthmatics aged 7 to 14 years, the frequency of
sensitization assessed by skin tests using a mixed extract of
B. germanica and P. americana amounted to 19.7% in
children with mild asthma, to 30.1% in children with moderate
asthma and to 40.7% in those with severe asthma, with a
statistically significant difference.3 Since only 7% of our
asthmatic patients had severe asthma, we categorized them
into two groups in order to assess sensitization according to
disease severity: mild asthma (46%) and moderate/severe
asthma (54%). Sensitization to B. germanica and/or P.
americana among patients with moderate/severe asthma in
relation to those patients with mild asthma amounted
respectively to 41.5 versus 25.7% on the skin tests and to
51.2 versus 34.3% in the specific IgE measurement. No
statistically significant difference was observed.
We may not have found a significant difference due to the
sample size used, which was not calculated specifically for
this purpose, or due to the small number of patients classified
as having severe asthma. Although the samples were collected
from an allergic disease outpatient clinic, approximately 50%
of patients had mild asthma, associated with more severe
symptoms of allergic rhinitis. This may explain the high rate
of cockroach sensitization in this group (25.7% on skin tests
and 34.3% in the specific IgE measurement).
Since the levels of allergen exposure in patients households
were not determined, the analysis of asthma severity was
limited to the assessment of cockroach sensitization, which,
in isolation, is not associated with more severe disease.4 It
was not possible to quantify exposure in households through
monoclonal antibody assays. Therefore, data about exposure
were obtained from the subjective impression of parents or
surrogates about the presence of cockroaches in the household
in the last 6 months. However, visual impression is not a good
marker of allergen exposure, as allergens are detected in
household dust in up to 48% of cases in which no signs of
infestation exist.5
In case of a patient with a clinical picture that suggests
allergic disease, clinical history and physical examination
often have to be complemented with laboratory tests.
Symptoms are usually common to other morbidities, and
allergens from different sources may be involved. This is
especially complex when perennial symptoms are considered,
i.e., when there is no clear association between the exposure
to a specific allergen and the development of symptoms, in
addition to the difficulty surrounding the difference between
sensitization and atopic disease, since many individuals with
sensitization to inhalant allergens do not present with asthma
and/or allergic rhinitis symptoms.6
Our study does not provide direct evidence that
cockroaches caused asthma among the children and
adolescents assessed. From the association between
cockroach sensitization, either by the skin test or by
specific IgE measurement, and asthma, our conclusion is
that this sensitization may be an important risk factor for
the disease. Nevertheless, only a more in-depth longitudinal
study with a multivariate analysis model including the
various risk factors involved will allow determining the
actual effect of cockroach sensitization on asthma risk and
severity.
Dear Editor,
We greatly appreciate the comments by Camelo-Nunes
and SolØ about our article on cockroach sensitization.1
Cockroach allergy has been known for over 40 years and,
since then, studies have been carried out worldwide, showing
the association between the development of specific IgE
antibodies against cockroach allergens and asthma. Despite
this fact, even in the USA, where most of the research on this
topic is conducted, parents or surrogates of asthmatic children
associate the cause of asthma attacks with tobacco smoke,
fungi, dust, and inhaled irritants, but not with cockroaches.2
As exposure is chronic, and often goes unnoticed by household
members because cockroaches hide from view most of the
time, living in a parallel universe, there is usually no reference
to the development of symptoms as a result of exposure to
cockroaches.
Some studies have suggested that asthmatic individuals
with cockroach sensitization belong to a distinct subgroup
doi:10.2223/JPED.1540
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Serum prevalence of celiac disease
in children and adolescents
with type 1 diabetes mellitus
Dear Editor,
We would like to make some comments about the article
entitled Serum prevalence of celiac disease in children and
adolescents with type 1 diabetes mellitus.1
In most diabetic patients, celiac disease (CD) is insidious
and asymptomatic; therefore, serological screening for CD is
crucial for an early diagnosis and introduction of appropriate
treatment.2 In a cross-sectional study, Araœjo et al.1 found a
prevalence of 10.5% for CD among children and adolescents
with type 1 diabetes mellitus (DM-1) using the anti-tissue
transglutaminase (anti-tTG) antibody assay, recommended
as the test of choice for the initial screening of CD in diabetic
patients.3
Serological tests for the detection of anti-tTG and anti-
endomysial antibodies should be reserved for IgA isotypes;
therefore, it is necessary to identify patients with IgA deficiency
(IgAD) beforehand in order to rule out false-negative results.
Of 361 diabetic patients selected by Araœjo et al.1, seven
(1.9%) had IgAD.
In a previous study carried out at Hospital de Clínicas of
Universidade Federal do ParanÆ, Brazil, eight out of 149
diabetic children and adolescents screened for CD had IgAD
(IgA < 5 mg/dL), which corresponds to a prevalence of 5.3%.
Serum IgA levels were measured by the enzyme-linked
immunosorbent assay (ELISA), standardized to determine
serum IgA titers below the radial immunodiffusion sensitivity
level in the low-concentration plate and turbidimetry. In this
same group of diabetic patients, the diagnosis of CD was
confirmed in 8.7% (13/149) by anti-endomysial antibody
testing and intestinal biopsy.4
Liblau et al.5 reported that one out of 261 diabetic patients
in France had IgAD, a higher prevalence rate than that for the
normal French population, which corresponds to 1:1,400. In
Italy, IgAD was detected in seven of 191 diabetic patients,
i.e., a prevalence of 1:27, higher than that for the normal
Italian pediatric population (1:500).6
The prevalence of CD in DM-1 patients, recently assessed
by anti-endomysial antibody testing and intestinal biopsy in
the state of Sªo Paulo, Brazil, amounted to 4.8%, comparable
to the prevalence rate described in U.S. and European
studies.7
Tanure et al. found a prevalence of 2.6% for CD in diabetic
patients from the Brazilian state of Minas Gerais.8 The
patients were identified based on the positive results for
antigliadin antibodies (AGA), anti-endomysial antibodies and
intestinal biopsy.7 However, only diabetic patients with positive
IgG-AGA and negative IgA-AGA results had their IgA level
measured by nephelometry. The 12 patients who were positive
only for IgG-AGA had normal serum IgA levels.
We agree that multicenter studies should be conducted in
Brazil on the association of CD and DM-1 and that diabetics
should be screened for CD on a routine basis. However, due
to the higher prevalence of IgAD among diabetic patients, the
serum IgA level should be determined before the serological
tests for the detection of anti-tTG and anti-endomysial
antibodies of the IgA isotype class for the screening of CD.
This eliminates false-negative results, by the use of criteria
established for IgAD, and by more sensitive methods for IgA
measurement, such as ELISA (Table 1).
Table 1 - Prevalence of IgAD and CD in DM-1 patients,
according to different studies
CD = celiac disease; IgAD = IgA deficiency; DM-1 = type 1 diabetes mellitus;
NP = not performed.
* Criteria for IgAD: serum IgA < 5 mg/dL.
DM-1 IgAD CD
Curitiba, Brazil4 149 8 (5.3%) * 13 (8.7%)
Belo Horizonte, Brazil8 234 ? 6 (2.6%)
Sªo Paulo, Brazil7 104 3 (2.9%) 5 (4.8%)
Recife, Brazil1 354 7 (2.0%) 37 (10.5%)
France5 261 1 (0.4%) NP
Italy6 191 7 (3.6%) NP
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